Belhaven Biopharma Study Shows Promising Results for Nasal Epinephrine Delivery

Belhaven Biopharma, a leader in emergency use dry powder nasal products, has announced promising results from their latest nonclinical study. Presented at Respiratory Drug Delivery (RDD) 2024, the Nasdepi Canine Study compared the pharmacokinetics of dry powder nasal epinephrine to the traditional autoinjector.

The study suggests that the new nasal solution provides faster and more effective treatment for anaphylaxis resulting from severe allergies. "Intranasal administration of dry powder epinephrine achieves a more rapid onset of action than the FDA-approved autoinjector," stated Scott Lyman, CEO of Belhaven Biopharma.

Conducted in collaboration with Lovelace Biomedical, the study highlighted several advantages of the nasal delivery method, including rapid effectiveness, increased drug exposure, and potential for better patient compliance. The intranasal administration achieved maximum plasma concentrations within 5 minutes, significantly faster than traditional methods.

The research involved four female beagle dogs and included various plasma sample collections to measure epinephrine concentrations. Key findings indicate not only faster delivery but also a longer duration of effective concentration compared to autoinjectors.

Following these promising results, further investigation into the efficacy and safety of the nasal dry powdered epinephrine for treating anaphylaxis is anticipated. A recent pilot clinical study in healthy human subjects also supports these findings.